Skip to main content

Table 2 Clinicopathologic variables and NUCB2 protein expression in 180 PCa patients

From: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer

Variable Group NUCB2 protein expression P value
n High Low
Age      0.897
<70 97 54 (55.7%) 43 (44.3%)  
≥70 83 47 (56.6%) 36 (43.4%)  
Lymph node metastasis      0.022
Positive 17 14 (82.4%) 3 (17.6%)  
Negtive 163 87 (53.4%) 76 (46.6%)  
Surgical margin status      0.521
Positive 14 9 (64.3%) 5 (35.7%)  
Negtive 166 92 (55.4%) 74 (44.6%)  
Seminal vesicle invasion      0.016
Positive 35 26 (74.3%) 9 (25.7%)  
Negtive 145 75 (51.8%) 70 (48.3%)  
PCa stage      0.114
T1 103 63 (61.2%) 40 (38.8%)  
T2/T3 77 38 (49.4%) 39 (50.6%)  
Preoperative PSA      0.006
<4 5 1 (20%) 4 (80%)  
4-10 64 28 (43.8%) 36 (56.2%)  
>10 111 72 (64.9%) 39 (35.1%)  
Gleason score      0.017
<7 99 47 (47.5%) 52 (52.5%)  
7 34 20 (58.8%) 14 (41.2%)  
>7 47 34 (72.3%) 13 (27.7%)  
Angiolymphatic invasion      0.042
Positive 35 25 (71.4%) 10 (28.6%)  
Negtive 145 76 (52.4%) 69 (47.6%)  
Biochemical recurrence      0.003
Absence 128 63 (49.2%) 65 (50.8%)  
  Presence 52 38 (73.1%) 14 (26.9%)